Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 20 August 2025

Sec. Vaccines and Molecular Therapeutics

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1682368

Correction: The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases

This article is a correction to:

  1. The Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine in Individuals with Chronic Diseases

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

A Correction on
The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases

By Tang W, Lu X, Zhu Z, Yu D, Liu H, Song Y, Shen L, Yu Y, Zhao Y and Xie Y (2025). Front. Immunol. 16:1624095. doi: 10.3389/fimmu.2025.1624095

The Reviewer Ahmed Tawfik Moustafa’s affiliation “Institut Pasteur de Paris, France” was erroneously given as “Institut Pasteur de Lille, France”.

The original version of this article has been updated.

Keywords: chronic disease, inactivated quadrivalent influenza vaccine, 23-valent pneumococcal polysaccharide vaccine, simultaneous administration, immunogenicity, safety

Citation: Frontiers Production Office (2025) Correction: The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases. Front. Immunol. 16:1682368. doi: 10.3389/fimmu.2025.1682368

Received: 08 August 2025; Accepted: 08 August 2025;
Published: 20 August 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, bWFpbHRvOnByb2R1Y3Rpb24ub2ZmaWNlQGZyb250aWVyc2luLm9yZw==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.